FCN2 and chronic kidney disease: Using clinical, laboratory and baseline proteomic data collected in the EQUAL Study, three proteins—Receptor protein-tyrosine phosphatase sigma, FCN2 and IGFBP6—were identified as having an association with eGFR decline in two independent sub-cohorts of older Europeans with advanced CKD.